ArticleCancer biology & medicine2024

Osimertinib exacerbates immune checkpoint inhibitor-related severe adverse events by activating the IL-6/JAK/STAT3 pathway in macrophages.

Yuan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.